Diaceutics PLC

What is the missed opportunity and economic impact of suboptimal biomarker testing in clinical practice today? Precision oncology has a significant role to play in delivering optimal patient outcomes with actionable biomarkers as the critical enabler, including its application in supporting early diagnosis, defining prognosis and accelerating patient access to safe and effective therapies. However, despite these life changing improvements to patient care, significant advances in genomic testing and extensive research demonstrating;   1) How precision oncology, when implemented correctly, can deliver considerable economic value at a clinical level saving US$1.1 billion in R&D costs and significantly reducing time intervals for taking drugs to market (R.H. Henderson, et al. Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach. (https://lnkd.in/dPrdySCi) J Pharm Policy Pract, 16 (1) (2023), p. 84). 2) The impact to patients, with 49.7% of patients lost along the treatment pathway due to clinical gaps, including poor implementation and management of biomarker testing (Helen Sadik, PhD. 2022. “Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer.” (https://lnkd.in/e2M_iJ5n) JCO Precision Oncology Volume 66). We continue to see failings with biomarker testing not being exploited in clinical settings, resulting in missed opportunities to deliver the most effective cancer care model for patients. In the recently published paper co-written by our founder Peter Keeling, “Empowering effective biomarker-driven precision oncology: A call to action,” we look to assess the factors that currently hinder the routine adoption of biomarker testing including; cost, lack of test reimbursement, limited access, regulatory hurdles, lack of knowledge and the urgent need to harmonize and validate testing assays, all of which lead to inefficient diagnostic pathways. This paper validates and further emphasizes the issues Diaceutics has been advocating for over the last 19 years, most recently within the Economic, Policy & Operational Solutions Global Summit. Here, the members of our Forum of key stakeholders within the precision medicine industry outlined a series of recommendations to address the economic, operational, and policy changes required to ultimately support the mainstreaming of biomarker-informed precision oncology, enabling a 21st century cancer care model for all patients. Read the full publication here: https://lnkd.in/dJE_8QJ6 Watch the Economic Summit here: https://lnkd.in/erK55QSe 

Do you need to increase your biomarker testing rates? Findings from our recent ASCO poster revealed that 33% of selected physicians were successfully engaged following a DXRX Physician Engage outreach campaign, leading to 81 new therapy-eligible patients being identified who might have otherwise been overlooked in routine clinical practice. DXRX Physician Engage utilizes our direct-from-lab data from over 500 US labs to pinpoint and engage relevant physicians in as little as 24 hours post biomarker testing. Our in-house precision medicine content writers create tailored educational messages to engage target physicians, educating them on your therapy within the critical treatment decision timeframe, leading to increased biomarker testing rates and ultimately better patient outcomes. Don’t miss the critical window of engagement - talk to our team today. Find out more about DXRX Physician Engage here: https://lnkd.in/dZNqWKgE #PrecisionMedicine #BetterTesingBetterTreatment

At Diaceutics, it's our people and their expertise that make us a truly exceptional company. We are proud to showcase the incredible talent within our team, and over the next few months, we will be spotlighting some of our outstanding employees, starting with our VPs. Stay tuned as we highlight the stories, achievements, and insights our leaders who are driving innovation and excellence within our industry. First up, we are featuring Ken Ruppel, our new VP of Scientific and Medical Services. In an interview just published, Ken shares his incredible journey, career highlights, and valuable insights into the world of precision medicine. Don’t miss out on this inspiring read! 👉 Read the full interview on our website: https://lnkd.in/eXJrSMtn #PrecisionMedicine #LifeSciences #MedicalResearch #Pharmaceuticals #ClinicalDiagnostics #Leadership #Innovation

Recent findings from our ASCO poster revealed that 33% of selected physicians were successfully engaged following a DXRX Physician Engage outreach campaign, ultimately leading to 81 new therapy-eligible patients being identified who might have otherwise been overlooked in routine clinical practice. DXRX Physician Engage utilizes our direct-from-lab data from over 500 US labs to pinpoint and engage relevant physicians in as little as 24 hours post biomarker testing. Our in-house precision medicine content writers use their expertise to create tailored educational messages to gain engagement from your target physicians, driving better patient outcomes and leading to increased biomarker testing rates. Find out more about DXRX Physician Engage here: https://lnkd.in/eHyH_bKA #PrecisionMedicine #BetterTesingBetterTreatment

We were joined by Professor Gian Franco Zannoni professor of Pathology at Catholic University of Sacred Heart, and Chief of the Department of General Pathology at Polyclinic in Rome as he offered his feedback on the report “Biomarkers characterization in Endometrial Cancer in Europe.”    Professor Zannoni shares his experience of European collaboration on endometrial cancer testing, the impact of this collaboration study on the scientific laboratory community and working with Diaceutics on the project.     Collaborating with Diaceutics provided a platform for European laboratories to easily connect and network together to create this report.     You can read the report now - https://lnkd.in/e7uYfZQU   Are you a member of our DXRX network?      You can gain immediate access to our Endometrial Cancer European Biomarker data dashboard - https://lnkd.in/eQca8xc9      Not a member yet?      You can register to become a member NOW, just follow the link below: https://lnkd.in/enF9nuCf

What if you could identify and engage exact physicians with a biomarker positive patient within hours of a patient testing positive? Would this help increase your testing rate? Our Clinical Practice Gaps study, published in the JCO Precision Oncology in 2022* revealed that approximately 64% of potentially eligible patients are lost due to gaps in clinical practice along the patient journey. A significant factor in these missed treatment opportunities is the low prevalence of biomarker testing, often linked to insufficient physician awareness. DXRX Physician Engage enables you to deliver timely, relevant and real-world data-driven messages to physicians treating therapy-eligible patients in as little as 24 hours, educating them on your therapy within the critical treatment decision timeframe, leading to increased biomarker testing rates. Don’t miss the critical window of engagement – talk to us about Physician Engage today. Learn more here: https://lnkd.in/dZNqWKgE *(Sadik et al., JCO 2022) #PrecisionMedicine #BetterTesingBetterTreatment

Don’t miss out and join us for the next instalment of the ‘Precision medicine in oncology’ series titled, ‘Pediatric tumors: Brain and hematological tumors’ with guest speakers Dr. Maura Massimino and Dr. Olga Weinberg.  This event will focus on including identification of biomarkers, discussion of the testing landscape, and review of potential diagnostic hurdles. Date: 18th July  Time: 3pm CEST  Sign up now! https://lnkd.in/d9KrMdKR

Happy 4th of July to all our American clients and colleagues! Wishing you all a joyful Independence Day filled with fun and memorable celebrations from everyone at Diaceutics! #IndependenceDay #precisionmedicine

Endometrial carcinoma (EC) is the most common gynecological cancer affecting women in Western populations! Read our latest report now to learn about the daily practice in Europe in Endometrial Carcinoma evaluation: https://lnkd.in/e7uYfZQU Are you a member of our DXRX network?   You can gain immediate access to our Endometrial Cancer European Biomarker data dashboard now: https://lnkd.in/eQca8xc9 Not a member yet?   You can register to become a member today: https://lnkd.in/enF9nuCf

Introducing our new Discover DXRX Data Fact Sheet Series! NSCLC constitutes a staggering 85% of all lung cancer cases. In the US, biomarker testing plays a pivotal role in tailoring treatments. By assessing genetic mutations and protein expressions, clinicians can select optimal therapies, emphasizing the critical importance of understanding the biomarker landscape in NSCLC. Join us on this data-driven journey as we explore the exciting world of DXRX data capabilities! Read our latest fact sheet here: https://lnkd.in/eKCjB2yn #PrecisionMedicine #DXRXData #Biomarkers #NSCLC #Realworlddata